Tenebroso, Maria Merlie Jane D.
HRN: 23-88-81 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/12/2023
CEFTAZIDIME 1GM (VIAL)
10/12/2023
10/19/2023
IV
1g
Q8
CAP-MR; PTB Presumptive
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes